F S&P 500
5,249.00 +2.75 (+0.05%) F Dow Jones
39,644.00 +2.00 (+0.01%) F Nasdaq
18,276.75 +21.75 (+0.12%) E-mini Russell 2000 Index Futur
2,070.80 +2.90 (+0.14%) Petróleo
78.04 -0.22 (-0.28%) Oro
2,363.90 -11.10 (-0.47%)
NextCure, Inc. (2US.F)
NextCure, Inc.
9000 Virginia Manor Road
Suite 200
Beltsville, MD 20705
United States
240 399 4900
https://www.nextcure.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 82
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael S. Richman MSBA | Co-Founder, CEO, President & Director | 651.64k | N/D | 1961 |
| Dr. Solomon Langermann Ph.D. | Chief Scientific Officer | 494.82k | N/D | 1960 |
| Dr. Han Myint FACP, M.D. | Chief Medical Officer | 510.07k | N/D | 1954 |
| Dr. Lieping Chen M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | N/D | N/D | 1957 |
| Dr. Timothy Mayer Ph.D. | Chief Operating Officer | N/D | N/D | 1965 |
| Mr. Kevin G. Shaw | Senior VP & General Counsel | N/D | N/D | 1975 |
| Ms. Stacy Rollinger | Vice President of Human Resources | N/D | N/D | N/D |
| Mr. Sourav Kundu Ph.D. | Senior Vice President of Development & Manufacturing | N/D | N/D | 1961 |
| Dr. Sebastien Maloveste | Senior Vice President of Business Development | N/D | N/D | N/D |
| Dr. Udayan Guha M.D., Ph.D. | Senior Vice President of Clinical & Translational Development | N/D | N/D | N/D |
Descripción
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Gestión corporativa
La calificación ISS Governance QuickScore de NextCure, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 5; Junta: 5; Derechos del accionista: 5; Compensación: 9.
